MDS
Clinical trials for MDS explained in plain language.
Never miss a new study
Get alerted when new MDS trials appear
Sign up with your email to follow new studies for MDS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug regimen beat the standard for stem cell transplant complications?
Disease control OngoingThis trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…
Matched conditions: MDS
Phase 3 • Sponsor: DKMS gemeinnützige GmbH • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant in kids
Disease control OngoingThis study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…
Matched conditions: MDS
Phase 2 • Sponsor: Franziska Wachter • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control CancelledThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Matched conditions: MDS
Phase 1/2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Younger donors may improve stem cell transplant success for leukemia patients
Disease control OngoingThis study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…
Matched conditions: MDS
Phase 3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo tackles relapsed blood cancers after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment…
Matched conditions: MDS
Phase 1/2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy shows promise for rare blood cancers
Disease control OngoingThis study looks at whether adding venetoclax to standard chemotherapy (HMAs) works better than chemotherapy alone for people newly diagnosed with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 224 adults are being observed to see how…
Matched conditions: MDS
Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could your phone camera replace blood tests? new study explores
Knowledge-focused OngoingThis study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Over 6 months, participants use a smartphone app to answer weekly quality-of-life questions and take photos of their fingernails or eyelids. Researchers aim …
Matched conditions: MDS
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC